OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+13.93%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$494M
AUM Growth
+$494M
(+10%)
Cap. Flow
+$17.1M
Cap. Flow
% of AUM
3.47%
Top 10 Holdings %
Top 10 Hldgs %
73.47%
Holding
50
New
5
Increased
15
Reduced
12
Closed
9
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$8.55M |
| 2 |
VIGL
Vigil Neuroscience
VIGL
|
$7.95M |
| 3 |
Codexis
CDXS
|
$7.56M |
| 4 |
Larimar Therapeutics
LRMR
|
$6.35M |
| 5 |
Disc Medicine
IRON
|
$5.37M |
Top Sells
| 1 |
Ginkgo Bioworks
DNA
|
$7.82M |
| 2 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$4.82M |
| 3 |
AnaptysBio
ANAB
|
$4.66M |
| 4 |
SLRN
ACELYRIN
SLRN
|
$3.99M |
| 5 |
Protara Therapeutics
TARA
|
$2.65M |
Sector Composition
| 1 | Healthcare | 97.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CRGX
26
DELISTED
CARGO Therapeutics
CRGX
| $2.75M | 0.56% |
666,503
| – | – |
|
|
MBX
27
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $2.73M | 0.55% |
239,319
-10,681
| -4% | -$122K |
|
28
Zymeworks
ZYME
$1.12B
| $2.64M | 0.53% |
210,000
+35,000
| +20% | +$439K |
|
|
29
Protara Therapeutics
TARA
$120M
| $2.59M | 0.52% |
855,000
-875,000
| -51% | -$2.65M |
|
|
ALMS
30
Alumis Inc. Common Stock
ALMS
$479M
| $2.33M | 0.47% |
+775,000
| New | +$2.33M |
|
31
Zentalis Pharmaceuticals
ZNTL
$122M
| $2.23M | 0.45% |
1,924,300
-60,700
| -3% | -$70.4K |
|
32
Trevi Therapeutics
TRVI
$883M
| $2.13M | 0.43% |
390,000
-405,000
| -51% | -$2.22M |
|
33
Avita Medical
RCEL
$116M
| $2.06M | 0.42% |
389,519
-50,481
| -11% | -$267K |
|
|
IRD
34
Opus Genetics, Inc. Common Stock
IRD
$73.1M
| $1.15M | 0.23% |
1,220,000
+45,000
| +4% | +$42.4K |
|
35
Journey Medical
DERM
$176M
| $682K | 0.14% |
95,000
+25,677
| +37% | +$184K |
|
|
ELEV
36
DELISTED
Elevation Oncology
ELEV
| $529K | 0.11% |
+1,442,061
| New | +$529K |
|
37
iBio
IBIO
$15.9M
| $285K | 0.06% |
375,000
| – | – |
|
38
PepGen
PEPG
$38M
| $266K | 0.05% |
240,000
-180,000
| -43% | -$200K |
|
|
ADGM
39
Adagio Medical Holdings, Inc Common Stock
ADGM
$24.8M
| $144K | 0.03% |
110,571
| – | – |
|
|
40
AnaptysBio
ANAB
$569M
| – | – |
-250,933
| Closed | -$4.66M |
|
41
Biodesix
BDSX
$63.6M
| – | – |
-3,225,000
| Closed | -$2.02M |
|
42
Kiniksa Pharmaceuticals
KNSA
$2.48B
| – | – |
-62,501
| Closed | -$1.39M |
|
43
Nurix Therapeutics
NRIX
$714M
| – | – |
-115,000
| Closed | -$1.37M |
|
|
OPTN
44
DELISTED
OptiNose
OPTN
| – | – |
-193,039
| Closed | -$1.77M |
|
45
Sangamo Therapeutics
SGMO
$157M
| – | – |
-1,055,000
| Closed | -$692K |
|
|
SLRN
46
DELISTED
ACELYRIN
SLRN
| – | – |
-1,615,000
| Closed | -$3.99M |
|
47
Ventyx Biosciences
VTYX
$171M
| – | – |
-190,000
| Closed | -$219K |
|
|
PVLA
48
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| – | – |
-172,357
| Closed | -$4.82M |
|